--- schema_version: "secwatch.filing_event.v1" accession: "0001558370-23-017051" form_type: "8-K" ticker: "TECH" cik: "0000842023" company_name: "BIO-TECHNE Corp" filed_at: "2023-10-31T23:59:59+00:00" generated_at: "2026-06-09T05:15:42.142695+00:00" event_type: "earnings" sentiment: "negative" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed ## Summary - GAAP diluted EPS $0.31 vs $0.55 prior year; adjusted EPS $0.41 vs $0.45. - Revenue $276.9M, organic growth +2% (+3% reported). - ExoDx test volume +49%; GMP proteins revenue +39%; ProteinSimple +9% (ex-China +18%). - Cash from ops $59.4M, +6% YoY. - Declared quarterly dividend $0.08/share payable Nov 24; CEO Kim Kelderman effective Feb 1, 2024. ## SEC filing metadata - accession: 0001558370-23-017051 - form_type: 8-K - ticker: TECH - cik: 0000842023 - company_name: BIO-TECHNE Corp - filed_at: 2023-10-31T23:59:59+00:00 - event_type: earnings - sentiment: negative - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 2.02, 5.07, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/tmb-20231026x8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001558370-23-017051 - JSON: https://secwatch.observer/filing/0001558370-23-017051.json - Plain text: https://secwatch.observer/filing/0001558370-23-017051.txt ## Key facts - Earnings Releases BIO-TECHNE Corp reported first quarter ended September 30, 2023 results: revenue $276.9 million, EPS $0.31. - Period: first quarter ended September 30, 2023 - Revenue: $276.9 million - EPS: $0.31 - Result: reported results source text: its financial results for the first quarter ended September 30, 2023. ​ First Quarter FY2024 Highlights ​ ● First quarter organic revenue increased by 2% (3% reported) to $276.9 million. ​ ● GAAP earnings per share 1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS 1) of $0.41 compared to $0.45 one year ago. ​ ● Our ExoDx prostate test and GMP evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - Shareholder Votes BIO-TECHNE Corp shareholders approved Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm at the 2024-06-30 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2024-06-30 source text: Proposal No. 5 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024. 40 ​ For Against Abstain ​ 140,734,676 5,247,721 35,466 evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - Shareholder Votes BIO-TECHNE Corp shareholders approved Election of directors. - Proposal: director election - Outcome: passed source text: Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: ​ ​ For Against Abstain Broker Non-Vote Robert V. Baumgartner 100,149,013 41,734,415 66,390 4,068,045 Julie L. Bushman 132,251,087 9,638,369 60,362 4,068,045 John L. Higgins 116,991,416 24,891,094 67,308 4,068,045 Joseph D. Keegan 134,547,666 7,343,701 58,451 4,068,045 Charles R. Kummeth 139,037,662 2,847,756 64,400 4,068,045 Roeland Nusse 136,502,096 5,384,164 63,558 4,068,045 Alpna Seth 134,785,952 7,102,985 60,881 4,068,045 Randolph C. Steer 116,461,357 25,398,613 89,848 4,068,045 Rupert Vessey 134,555,098 7,335,534 59,186 4,068,045 Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation. evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - Shareholder Votes BIO-TECHNE Corp shareholders rejected Non-binding resolution approving the compensation of the Company’s named executive officers. - Proposal: say on pay - Outcome: failed source text: Proposal No. 3 – The shareholders voted against a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: 9, For Against Abstain Broker Non-Vote 49,894,295 91,277,734 777,789 4,068,045 evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - Shareholder Votes BIO-TECHNE Corp shareholders approved Frequency of future advisory votes on executive compensation to occur every year. - Proposal: say on pay frequency - Outcome: passed source text: Proposal No. 4 – The shareholders approved the frequency of future advisory votes on executive compensation to occur every year. 39 ​ 1 Year 2 Years 3 Years Abstain 139,718,743 141,528 939,375 1,150,172 evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm - Shareholder Votes BIO-TECHNE Corp shareholders approved Set the number of directors at nine. - Outcome: passed source text: Proposal No. 1 – The shareholders voted to set the number of directors at nine: ​ ​ For Against Abstain ​ 141,242,833 672,919 34,066 evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023017051/0001558370-23-017051-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.